Kanglexin

Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis[1][2][3][4].

Product Specifications

CAS Number

[2228847-12-7]

UNSPSC

12352005

Target

AMPK; ERK; FGFR; NOD-like Receptor (NLR) ; Pyroptosis

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics; Immunology/Inflammation; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/kanglexin.html

Concentration

10mM

Purity

99.65

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C1C2=C(C(C3=C(C=C(C)C=C13)O)=O)C(O)=CC(OC(CCC(OCC)=O)=O)=C2

Molecular Formula

C21H18O8

Molecular Weight

398.36

References & Citations

[1]Bian Y, et al. Kanglexin, a novel anthraquinone compound, protects against myocardial ischemic injury in mice by suppressing NLRP3 and pyroptosis. Acta Pharmacol Sin. 2020 Mar;41 (3) :319-326.|[2]Li X, et al. Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway. Biomed Pharmacother. 2021 Jan;133:110802. |[3]Yang S, et al. Kanglexin counters vascular smooth muscle cell dedifferentiation and associated arteriosclerosis through inhibiting PDGFR. Phytomedicine. 2024 Jul 25;130:155704. |[4]Zhao Y, et al. Kanglexin accelerates diabetic wound healing by promoting angiogenesis via FGFR1/ERK signaling. Biomed Pharmacother. 2020 Dec;132:110933.